drugset / Trial / NCT04515628
Study to Assess the Effect of Branebrutinib on the Drug Levels of Rosuvastatin in Healthy Participants
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to examine the interaction of branebrutinib with rosuvastatin. Rosuvastatin is a substrate of the breast cancer resistance protein (BCRP) transporter, which has a drug level profile that can be markedly altered by coadministration of known inhibitors of the BCRP transporter. With widespread use of statins as cholesterol-lowering agents, rosuvastatin is also a likely concomitant drug for participants who would potentially be treated with branebrutinib.
Timeline
- Start
- 2020-08-02
- Primary completion
- 2020-10-18
- Completion
- 2020-10-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Branebrutinib | Small molecule | — | — |
| Subject | Rosuvastatin | Small molecule | — | — |
Indications
No indication recorded.